Efficacy Observation Of Butylphthalide Injection Combined With Urinary Kallikrein Injection In Patients With Chronic Cerebral Circulatory Insufficiency

Objectives The clinical efficacy of using arterial spin labeling perfusion imaging observed Butylphthalide Injection combined with Urinary Kallikrein Injection treatment of chronic cerebral insufficiency,and in order to provide the basis for clinical treatment of CCCI.Methods 75 cases of chronic cerebral insufficiency patients who were included in the standard light in the Department of Neurology,the Hebei,Tangshan workers’ hospital during October 2015 to ctober 2016,will meet randomly divided into three groups,but in the combined treatment group,2 cases dropped off because of being treated with stent implantation,25 cases for the Butylphthalide Injection group,25 cases for the Urinary Kallikrein Injection group and 23 cases for combined treatment group.Three groups of patients were given conventional treatment,such as inhibition of platelet aggregation,antihypertensive treatment,hypoglycemic therapy and promoting blood circulation.The Butylphthalide Injection group uses Butylphthalide Injection with 100 ml,once a day for2 weeks.The Urinary Kallikrein Injection group were given Urinary Kallikrein 0.15 PNAU by intravenous drip once daily for 14 days.The combined treatment group was treated with Butylphthalide Injection and Urinary Kallikrein Injection,once a day for 2weeks.Observe in patients with ASL before and after treatment,ASL cerebral blood flow changes in the area of affected side and uninjured side,and the changes in r CBF values.Results 1The baseline data: There was no significant difference between the three groups in age,sex and risk factors,(P>0.05).2 ASL cerebral blood flow: the affected side CBF and r CBF of the three groups of patients after treatment were higher than those before treatment(P < 0.05),the uninjured CBF changes had no significant difference before and after treatment(P > 0.05).And the combined treatment group increased significantly compared with the Butylphthalide injection group and the Urinary Kallikrein injection group,and the difference was statistically significant(P < 0.05).3Comparison of clinical efficacy: after 14 days of treatment,the total effective rate of combined treatment group was 87%,higher than that of the Butylphthalide injection group(71%)and the Urinary Kallikrein injection group(68%),the difference was statistically significant(P<0.05).4The Urinary Kallikrein group had 1 adverse event,with 1 case in the combined treatment group,butylphthalide group did not appear adverse events.Only 2 cases of adverse events,there was no statistical significance.Conclusion We can observe that the treatmengt of Butyphthalide injection combined with Urinary Kallikrein injection improved the low perfusion of patients of CCCI using the magnetic resonance perfusion imaging of arteiral spin labeling,and it has significance for the prognostic evaluation of CCCI;the combined treatment can improve the low perfusion of CCCI patients,increase cerebral blood flow and play a significant role in improving the clinical symptoms.